St. Jude Medical announces results from POST-IT registry St. Jude Medical announced results from the POST-IT -- Portuguese Study on the Evaluation of FFR Guided Treatment of Coronary Disease -- registry were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. Data from the registry, which was sponsored by the Portuguese Association of Cardiovascular Interventions, demonstrated that the use of St. Jude Medical PressureWire fractional flow reserve technology changed the course of treatment for approximately half of the patients with coronary artery disease, thus ensuring patients with ischemia-producing narrowings received appropriate therapy.
St. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.